Strides Shasun Limited has received USFDA approval for the antihistamine Cetirizine Hydrochloride Capsules (liquid filled capsules) (OTC) to become the first Indian generic company to receive approval for Cetirizine (Softgel).

The product will be manufactured at the company's flagship facility at Bangalore and marketed by Strides Pharma Inc. in the U.S. market. The product is ready for launch immediately and as in the case of OTC products, the market formation takes time and the company expects to have an important market share in approximately six months.

According to IRI data, the U.S. market for Cetirizine Hydrochloride Capsules (Softgel) is approximately USD 60 million, with only one other generic player.

10 Diagnostic Imaging Trends for 2018


Digital version